₹27.49
Exchange Surveillance
- ASM Stage ILong Term Additional Surveillance Measure (LTASM) - Stage I
Price band ± 10% · narrower than the standard 20%
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Mangalam Drugs and Organics Limited is an India-based company engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates. The Companys segments include bulk drugs, and chemicals and others.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Mumbai, Maharashtra
- Chairman
- Govardhan M Dhoot
- CEO & MD
- Govardhan M Dhoot
- Registrar
- Link Intime India Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE584F01014
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Mangalam Drugs And Organics Limited today?
Mangalam Drugs And Organics Limited (MANGALAM) is trading at ₹27.49. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is MANGALAM’s P/E ratio versus the sector?
MANGALAM trades at a P/E of —. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is MANGALAM’s dividend yield?
MANGALAM has a dividend yield of 0.00%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is MANGALAM’s 52-week high and low?
MANGALAM has traded between ₹22.8 and ₹54.4 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Mangalam Drugs And Organics Limited?
Mangalam Drugs And Organics Limited has a market capitalisation of ₹45 crore.
▶What is MANGALAM’s return on equity?
MANGALAM reports a return on equity of -34.8%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are MANGALAM’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is MANGALAM’s promoter holding?
Promoters hold 35.65% of MANGALAM. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include MANGALAM?
Index membership is listed in the Context block on this page, along with the weight MANGALAM carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Mangalam Drugs And Organics Limited a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from MANGALAM’s own numbers. The judgement is yours.
MANGALAM at a glance
Mangalam Drugs And Organics Limited operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Mangalam Drugs And Organics Limited (MANGALAM) last traded at ₹27.49, giving it a market capitalisation of ₹45 crore. The 52-week range is ₹22.8 to ₹54.4, and the price is 15% of the way up that range. Promoters hold 35.65% of the company in the latest shareholding filing. Among 101 listed companies in the Drug Manufacturers - Specialty & Generic industry, Mangalam Drugs And Organics Limited is 99th by market capitalisation. The median price-to-earnings ratio across these companies is 33.3. Its return on equity of -35.4% compares with an industry median of 12.2%, ranking 98th of 100 peers reporting it.
| Market cap | ₹45 crore |
|---|---|
| ROE | -34.8% |
| ROCE | -13.8% |